Historical record - last NADAC effective date: 5/22/2019
Product Information
LAMIVUDINE-ZIDOVUDINE TABLET is a generic product labeled by Exelan Pharmaceuticals Inc., priced at $1.2739 per EA under NDC 76282011560. Its NADAC has been published 187 times since Oct 28, 2015.
FDA first approved this application on Feb 3, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150; 300 mg/1; mg/1
Manufacturer
Exelan Pharmaceuticals Inc.NDC
76282011560
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
5/22/2019
Active Ingredients
LAMIVUDINE; ZIDOVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA203259FDA Approved
2/3/2014
TE Code
AB
On Market Since
4/29/2015
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has been published 187 times since Oct 28, 2015, and over the history we have for it it has declined 65.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2739 per EA |
|---|---|
| All-time high | $4.0868 (Feb 10, 2016) |
| All-time low | $0.8983 (Nov 21, 2018) |
| Median price | $1.6395 |
| Average price | $1.9239 |
| Largest weekly change | +46.1% (Dec 19, 2018) |
| Weeks tracked | 187 |
| Tracking since | Oct 28, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
-65.7%
Last surveyed May 22, 2019 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 42% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of LAMIVUDINE-ZIDOVUDINE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE-ZIDOVUDINE TABLET, manufactured by Exelan Pharmaceuticals Inc., is $1.2739 per EA (NDC 76282011560), effective May 22, 2019.
How has the price of LAMIVUDINE-ZIDOVUDINE TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has declined 65.7%. It has been tracked across 187 weekly CMS publications since Oct 28, 2015.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE-ZIDOVUDINE TABLET?
Since Oct 28, 2015, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has ranged from a low of $0.8983 (Nov 21, 2018) to a high of $4.0868 (Feb 10, 2016), with a median of $1.6395 per EA.
Are there cheaper alternatives to LAMIVUDINE-ZIDOVUDINE TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LAMIVUDINE-ZIDOVUDINE TABLET, is $0.7351 per EA — about 42% below LAMIVUDINE-ZIDOVUDINE TABLET.
Who manufactures LAMIVUDINE-ZIDOVUDINE TABLET?
LAMIVUDINE-ZIDOVUDINE TABLET (NDC 76282011560) is labeled by Exelan Pharmaceuticals Inc., and CMS classifies it as a generic product.